[ad_1] Results from a Phase 3 clinical trial, CAPSTONE-2, evaluating Genentech's Balboxavir Marboxil at Roche (OTCQX: RHHBY) in patients at high risk of influenza-related complications have shown therapeutic benefits. The data was …
Read More »Roche's oral flu has a positive effect in an advanced phase study – Roche Holding Ltd ADR (OTCMKTS: RHHBY)
